share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  11/13 20:33

Moomoo AI 已提取核心信息

Clene Inc. (Clene) reported a net loss of $7.986 million for the third quarter ended September 30, 2024, compared to a net loss of $2.418 million for the same period in 2023. The diluted net loss per share was $1.22 for the quarter, a significant increase from $0.38 in the previous year. The company's revenue from related parties for the quarter was $86,000, a decrease from $107,000 in the prior year. Clene also closed a registered direct offering on October 1, 2024, with gross proceeds of approximately $3.5 million before fees and expenses. In business development, Clene amended its License and Supply Agreements with 4Life, granting exclusive rights to purchase and sell certain dietary supplements. Clene provides Zinc Factor™ and Gold Factor™ supplements to 4Life. The company's future plans include continuing clinical trials for its lead drug candidate, CNM-Au8, in various central nervous system disorders, with a focus on ALS, MS, and PD. Clene is also evaluating the accounting for proceeds from the recent offerings and the classification of associated equity securities.
Clene Inc. (Clene) reported a net loss of $7.986 million for the third quarter ended September 30, 2024, compared to a net loss of $2.418 million for the same period in 2023. The diluted net loss per share was $1.22 for the quarter, a significant increase from $0.38 in the previous year. The company's revenue from related parties for the quarter was $86,000, a decrease from $107,000 in the prior year. Clene also closed a registered direct offering on October 1, 2024, with gross proceeds of approximately $3.5 million before fees and expenses. In business development, Clene amended its License and Supply Agreements with 4Life, granting exclusive rights to purchase and sell certain dietary supplements. Clene provides Zinc Factor™ and Gold Factor™ supplements to 4Life. The company's future plans include continuing clinical trials for its lead drug candidate, CNM-Au8, in various central nervous system disorders, with a focus on ALS, MS, and PD. Clene is also evaluating the accounting for proceeds from the recent offerings and the classification of associated equity securities.
Clene Inc.（Clene）报告截至2024年9月30日的第三季度净损失为798.6万美元，而2023年同期的净损失为241.8万美元。本季度每股摊薄净损失为1.22美元，较去年同期的0.38美元显著增加。该公司本季度来自关联方的营业收入为86,000美元，较上一年的107,000美元有所下降。Clene还于2024年10月1日完成了一项注册直接发行，毛收入约为350万美元，扣除费用和支出。在业务发展方面，Clene修改了与4Life的许可和供应协议，授予其独家购买和卖出某些膳食补充剂的权利。Clene向4Life提供Zinc Factor™和黄金Factor™补充剂。该公司的未来计划包括继续进行其主要药物候选者CNm-Au8的临床试验，针对各种中枢神经系统疾病，重点关注ALS、MS和PD。Clene还在评估最近发行的收益的会计处理以及相关股权证券的分类。
Clene Inc.（Clene）报告截至2024年9月30日的第三季度净损失为798.6万美元，而2023年同期的净损失为241.8万美元。本季度每股摊薄净损失为1.22美元，较去年同期的0.38美元显著增加。该公司本季度来自关联方的营业收入为86,000美元，较上一年的107,000美元有所下降。Clene还于2024年10月1日完成了一项注册直接发行，毛收入约为350万美元，扣除费用和支出。在业务发展方面，Clene修改了与4Life的许可和供应协议，授予其独家购买和卖出某些膳食补充剂的权利。Clene向4Life提供Zinc Factor™和黄金Factor™补充剂。该公司的未来计划包括继续进行其主要药物候选者CNm-Au8的临床试验，针对各种中枢神经系统疾病，重点关注ALS、MS和PD。Clene还在评估最近发行的收益的会计处理以及相关股权证券的分类。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间